Overview

Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the efficacy and safety of Pletaal (Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).
Phase:
Phase 2
Details
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Treatments:
Amlodipine
Cilostazol
Nitroglycerin